|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 2/23/17 Pfizer Inc 10-K 12/31/16 168:37M |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 504K
2: EX-10.4 Form of Stock Option Grant Notice and Summary of HTML 94K
Key Terms
4: EX-13 2016 Financial Report HTML 2.85M
5: EX-21 Subsidiaries of the Company HTML 150K
6: EX-23 Consent of Kpmg, Independent Registered Public HTML 63K
Accounting Firm
3: EX-12 Computation of Ratio of Earnings to Fixed Charges HTML 81K
7: EX-31.1 Certification by the Chief Executive Officer - 302 HTML 58K
8: EX-31.2 Certification by the Chief Financial Officer - 302 HTML 58K
9: EX-32.1 Certification by the Chief Executive Officer - 906 HTML 55K
10: EX-32.2 Certification by the Chief Financial Officer - 906 HTML 55K
17: R1 Document and Entity Information HTML 82K
18: R2 Consolidated Statements of Income HTML 146K
19: R3 Consolidated Statements of Comprehensive Income HTML 139K
20: R4 Consolidated Balance Sheets HTML 173K
21: R5 Consolidated Balance Sheets (Parenthetical) HTML 72K
22: R6 Consolidated Statements of Equity HTML 138K
23: R7 Consolidated Statements of Equity (Parenthetical) HTML 56K
24: R8 Consolidated Statements of Cash Flows HTML 196K
25: R9 Consolidated Statements of Cash Flows HTML 57K
(Parenthetical)
26: R10 Basis of Presentation and Significant Accounting HTML 143K
Policies
27: R11 Acquisitions, Assets and Liabilities Held for HTML 256K
Sale, Licensing Agreements, Research and
Development and Collaborative Arrangements,
Equity-Method Investments and Cost-Method
Investment
28: R12 Restructuring Charges and Other Costs Associated HTML 152K
with Acquisitions and Cost-Reduction/Productivity
Initiatives
29: R13 Other (Income)/Deductions - Net HTML 137K
30: R14 Tax Matters HTML 296K
31: R15 Accumulated Other Comprehensive Loss, Excluding HTML 102K
Noncontrolling Interests
32: R16 Financial Instruments HTML 398K
33: R17 Inventories HTML 69K
34: R18 Property, Plant and Equipment HTML 77K
35: R19 Identifiable Intangible Assets and Goodwill HTML 167K
36: R20 Pension and Postretirement Benefit Plans and HTML 907K
Defined Contribution Plans
37: R21 Equity HTML 84K
38: R22 Share-Based Payments HTML 295K
39: R23 Earnings Per Common Share Attributable to Pfizer HTML 106K
Inc. Common Shareholders
40: R24 Lease Commitments HTML 69K
41: R25 Insurance HTML 55K
42: R26 Commitments and Contingencies HTML 147K
43: R27 Segment, Geographic and Other Revenue Information HTML 422K
44: R28 Subsequent Event HTML 57K
45: R29 Basis of Presentation and Significant Accounting HTML 198K
Policies (Policies)
46: R30 Acquisitions, Assets and Liabilities Held for HTML 180K
Sale, Licensing Agreements, Research and
Development and Collaborative Arrangements,
Equity-Method Investments and Cost-Method
Investment (Tables)
47: R31 Restructuring Charges and Other Costs Associated HTML 147K
with Acquisitions and Cost-Reduction/Productivity
Initiatives (Tables)
48: R32 Other (Income)/Deductions - Net (Tables) HTML 139K
49: R33 Tax Matters (Tables) HTML 271K
50: R34 Accumulated Other Comprehensive Loss, Excluding HTML 98K
Noncontrolling Interests (Tables)
51: R35 Financial Instruments (Tables) HTML 390K
52: R36 Inventories (Tables) HTML 88K
53: R37 Property, Plant and Equipment (Tables) HTML 76K
54: R38 Identifiable Intangible Assets and Goodwill HTML 231K
(Tables)
55: R39 Pension and Postretirement Benefit Plans and HTML 956K
Defined Contribution Plans (Tables)
56: R40 Equity (Tables) HTML 66K
57: R41 Share-Based Payments (Tables) HTML 309K
58: R42 Earnings Per Common Share Attributable to Pfizer HTML 104K
Inc. Common Shareholders (Tables)
59: R43 Lease Commitments (Tables) HTML 66K
60: R44 Segment, Geographic and Other Revenue Information HTML 579K
(Tables)
61: R45 Basis of Presentation and Significant Accounting HTML 160K
Policies (Details)
62: R46 Acquisitions, Assets and Liabilities Held for HTML 92K
Sale, Licensing Agreements, Research and
Development and Collaborative Arrangements,
Equity-Method Investments and Cost-Method
Investment - Medivation, Inc. (Details)
63: R47 Acquisitions, Assets and Liabilities Held for HTML 95K
Sale, Licensing Agreements, Research and
Development and Collaborative Arrangements,
Equity-Method Investments and Cost-Method
Investment - Bamboo Therapeutics, Inc. (Details)
64: R48 Acquisitions, Assets and Liabilities Held for HTML 80K
Sale, Licensing Agreements, Research and
Development and Collaborative Arrangements,
Equity-Method Investments and Cost-Method
Investment - Anacor Pharmaceuticals, Inc.
(Details)
65: R49 Acquisitions, Assets and Liabilities Held for HTML 261K
Sale, Licensing Agreements, Research and
Development and Collaborative Arrangements,
Equity-Method Investments and Cost-Method
Investment - Hospira Acquisition (Details)
66: R50 Acquisitions, Assets and Liabilities Held for HTML 94K
Sale, Licensing Agreements, Research and
Development and Collaborative Arrangements,
Equity-Method Investments and Cost-Method
Investment - Additional Acquisitions (Details)
67: R51 Acquisitions, Assets and Liabilities Held for HTML 151K
Sale, Licensing Agreements, Research and
Development and Collaborative Arrangements,
Equity-Method Investments and Cost-Method
Investment - Assets and Liabilities Held for Sale
(Details)
68: R52 Acquisitions, Assets and Liabilities Held for HTML 86K
Sale, Licensing Agreements, Research and
Development and Collaborative Arrangements,
Equity-Method Investments and Cost-Method
Investment - Licensing Agreements (Details)
69: R53 Acquisitions, Assets and Liabilities Held for HTML 153K
Sale, Licensing Agreements, Research and
Development and Collaborative Arrangements,
Equity-Method Investments and Cost-Method
Investment - Research and Development and
Collaborative Arrangements (Detail)
70: R54 Acquisitions, Assets and Liabilities Held for HTML 103K
Sale, Licensing Agreements, Research and
Development and Collaborative Arrangements,
Equity-Method Investments and Cost-Method
Investment - Equity and Cost-Method Investments
(Details)
71: R55 Restructuring Charges and Other Costs Associated HTML 92K
with Acquisitions and Cost-Reduction/Productivity
Initiatives - Narrative (Detail)
72: R56 Restructuring Charges and Other Costs Associated HTML 100K
with Acquisitions and Cost-Reduction/Productivity
Initiatives - Costs (Detail)
73: R57 Restructuring Charges and Other Costs Associated HTML 99K
with Acquisitions and Cost-Reduction/Productivity
Initiatives - Costs - Footnotes (Detail)
74: R58 Restructuring Charges and Other Costs Associated HTML 78K
with Acquisitions and Cost-Reduction/Productivity
Initiatives - Restructuring Accruals (Detail)
75: R59 Restructuring Charges and Other Costs Associated HTML 62K
with Acquisitions and Cost-Reduction/Productivity
Initiatives - Restructuring Accruals - Footnotes
(Detail)
76: R60 Other (Income)/Deductions - Net (Details) HTML 94K
77: R61 Other (Income)/Deductions - Net - Footnotes - HTML 55K
Interest (Income) Expense (Details)
78: R62 Other (Income)/Deductions - Net - Footnotes - HTML 72K
Royalty Income (Details)
79: R63 Other (Income)/Deductions - Net - Footnotes - HTML 75K
Commitments and Contingencies (Details)
80: R64 Other (Income)/Deductions - Net - Footnotes - HTML 78K
Investments (Details)
81: R65 Other (Income)/Deductions - Net - Footnotes - HTML 104K
Indefinite-Lived Intangibles (Details)
82: R66 Other (Income)/Deductions - Net - Footnotes - HTML 58K
Finite-Lived Intangibles (Details)
83: R67 Other (Income)/Deductions - Net - Footnotes - HTML 80K
Additional Information (Details)
84: R68 Other (Income)/Deductions - Net - Additional HTML 92K
Information about Intangible Assets (Detail)
85: R69 Tax Matters - Income from Continuing Operations HTML 63K
Before Provision for Taxes on Income (Details)
86: R70 Tax Matters - Provision for Taxes on Income HTML 83K
(Details)
87: R71 Tax Matters - Provision for Taxes on Income HTML 62K
(Narrative) (Details)
88: R72 Tax Matters - Tax Rate Reconciliation (Details) HTML 81K
89: R73 Tax Matters - Deferred Taxes (Details) HTML 116K
90: R74 Tax Matters - Deferred Taxes - Footnotes (Details) HTML 63K
91: R75 Tax Matters - Narrative (Details) HTML 83K
92: R76 Tax Matters - Reconciliation of Gross Unrecognized HTML 75K
Tax Benefits (Details)
93: R77 Tax Matters - Reconciliation of Gross Unrecognized HTML 70K
Tax Benefits - Footnotes (Details)
94: R78 Tax Matters - Taxes on Items of Other HTML 102K
Comprehensive Income/(Loss) (Details)
95: R79 Accumulated Other Comprehensive Loss, Excluding HTML 81K
Noncontrolling Interests (Details)
96: R80 Accumulated Other Comprehensive Loss, Excluding HTML 56K
Noncontrolling Interests - Footnotes (Details)
97: R81 Accumulated Other Comprehensive Loss, Excluding HTML 61K
Noncontrolling Interests - Narrative (Details)
98: R82 Financial Instruments - Assets and Liabilities HTML 132K
Measured on Recurring Basis (Details)
99: R83 Financial Instruments - Assets and Liabilities HTML 98K
Measured on Recurring Basis - Footnotes (Details)
100: R84 Financial Instruments - Balance Sheet Grouping HTML 82K
(Details)
101: R85 Financial Instruments - Balance Sheet Grouping - HTML 89K
Footnotes (Details)
102: R86 Financial Instruments - Investments in Debt HTML 120K
Securities (Details)
103: R87 Financial Instruments - Narrative (Details) HTML 86K
104: R88 Financial Instruments - Long-Term Debt Narrative HTML 100K
(Details)
105: R89 Financial Instruments - Long-Term Debt (Details) HTML 139K
106: R90 Financial Instruments - Long-Term Debt - Footnotes HTML 70K
(Details)
107: R91 Financial Instruments - Long-Term Debt Outstanding HTML 69K
Maturities (Details)
108: R92 Financial Instruments - Derivative Financial HTML 136K
Instruments and Hedging Activities (Details)
109: R93 Inventories (Details) HTML 76K
110: R94 Property, Plant and Equipment (Details) HTML 99K
111: R95 Identifiable Intangible Assets and Goodwill - HTML 92K
Finite-lived and Indefinite-lived Intangible
Assets (Details)
112: R96 Identifiable Intangible Assets and Goodwill - HTML 68K
Finite-lived Intangible Assets Percentage of Total
Intangibles (Details)
113: R97 Identifiable Intangible Assets and Goodwill - HTML 68K
Indefinite-lived Intangible Assets Percentage of
Total Intangibles (Details)
114: R98 Identifiable Intangible Assets and Goodwill - HTML 65K
Narrative (Details)
115: R99 Identifiable Intangible Assets and Goodwill - HTML 64K
Expected Annual Amortization Expense (Details)
116: R100 Identifiable Intangible Assets and Goodwill - HTML 78K
Goodwill (Details)
117: R101 Pension and Postretirement Benefit Plans and HTML 68K
Defined Contribution Plans - Narrative (Details)
118: R102 Pension and Postretirement Benefit Plans and HTML 149K
Defined Contribution Plans (Details)
119: R103 Pension and Postretirement Benefit Plans and HTML 69K
Defined Contribution Plans - Amounts Expected to
be Amortized into Net Periodic Benefit Costs
(Details)
120: R104 Pension and Postretirement Benefit Plans and HTML 89K
Defined Contribution Plans - Weighted-Average
Actuarial Assumptions (Details)
121: R105 Pension and Postretirement Benefit Plans and HTML 62K
Defined Contribution Plans - Healthcare Cost Trend
Rate Assumptions (Details)
122: R106 Pension and Postretirement Benefit Plans and HTML 64K
Defined Contribution Plans - One-Percentage-Point
Increase or Decrease in the Healthcare Cost Trend
Rate (Details)
123: R107 Pension and Postretirement Benefit Plans and HTML 188K
Defined Contribution Plans - Obligations and
Funded Status (Details)
124: R108 Pension and Postretirement Benefit Plans and HTML 80K
Defined Contribution Plans - Funded Status
Recognized in Consolidated Balance Sheets
(Details)
125: R109 Pension and Postretirement Benefit Plans and HTML 75K
Defined Contribution Plans - Amounts Recognized in
Accumulated Other Comprehensive (Loss)/Income
(Details)
126: R110 Pension and Postretirement Benefit Plans and HTML 64K
Defined Contribution Plans - Amounts Recognized in
Accumulated Other Comprehensive (Loss)/Income -
Footnotes (Details)
127: R111 Pension and Postretirement Benefit Plans and HTML 74K
Defined Contribution Plans - Pension Plans in
Excess of Plan Assets (Details)
128: R112 Pension and Postretirement Benefit Plans and HTML 250K
Defined Contribution Plans - Plan Assets (Details)
129: R113 Pension and Postretirement Benefit Plans and HTML 92K
Defined Contribution Plans - Analysis of Changes
in Significant Investments Valued Using
Significant Unobservable Inputs (Details)
130: R114 Pension and Postretirement Benefit Plans and HTML 128K
Defined Contribution Plans - Long-term Target
Asset Allocations Ranges and the Percentage of the
Fair Value of Plan Assets (Detail)
131: R115 Pension and Postretirement Benefit Plans and HTML 107K
Defined Contribution Plans - Expected Future Cash
Flow Information (Details)
132: R116 Equity - Summary of Common Stock Purchases HTML 64K
(Details)
133: R117 Equity - Narrative (Details) HTML 112K
134: R118 Share-Based Payments - Narrative (Detail) HTML 83K
135: R119 Share-Based Payments - Impact on Net Income HTML 76K
(Detail)
136: R120 Share-Based Payments - Restricted Stock Unit HTML 87K
Activity (Detail)
137: R121 Share-Based Payments - Data Related to All HTML 62K
Restricted Stock Unit Activity (Detail)
138: R122 Share-Based Payments - Stock Option Narrative HTML 62K
(Details)
139: R123 Share-Based Payments - Valuation Assumptions of HTML 67K
Stock Options (Detail)
140: R124 Share-Based Payments - Stock Option Activity HTML 107K
(Detail)
141: R125 Share-Based Payments - Data Related to All Stock HTML 70K
Option Activity (Detail)
142: R126 Share-Based Payments - Portfolio Performance HTML 65K
Shares Narrative (Details)
143: R127 Share-Based Payments - Portfolio Performance HTML 82K
Shares Activity (Details)
144: R128 Share-Based Payments - Data Related to All HTML 62K
Portfolio Performance Shares Activity (Details)
145: R129 Share-Based Payments - Total Shareholder Return HTML 72K
Units Narrative (Details)
146: R130 Share-Based Payments - Valuation Assumptions of HTML 66K
Total Shareholder Return Units (Detail)
147: R131 Share-Based Payments - Total Shareholder Return HTML 91K
Units Activity (Details)
148: R132 Share-Based Payments - Outstanding Total HTML 98K
Shareholder Return Units Activity (Details)
149: R133 Share-Based Payments - Data Related to All Total HTML 62K
Shareholder Return Units (Details)
150: R134 Share-Based Payments - Performance Share Awards HTML 68K
(PSAs) Narrative (Details)
151: R135 Share-Based Payments - Performance Share Awards HTML 77K
(PSAs) Activity (Details)
152: R136 Share-Based Payments - Data Related to All HTML 62K
Performance Share Awards (PSAs) (Details)
153: R137 Earnings Per Common Share Attributable to Pfizer HTML 109K
Inc. Common Shareholders - Basic and Diluted
Numerator and Denominator (Details)
154: R138 Lease Commitments (Detail) HTML 73K
155: R139 Commitments and Contingencies (Action In Which We HTML 97K
Are the Plaintiff) (Details)
156: R140 Commitments and Contingencies (Action In Which We HTML 88K
Are The Defendant) (Details)
157: R141 Commitments and Contingencies (Certain Matters HTML 97K
Resolved And Purchase Commitments) (Details)
158: R142 Segment, Geographic and Other Revenue Information HTML 102K
- Narrative (Detail)
159: R143 Segment, Geographic and Other Revenue Information HTML 99K
(Detail)
160: R144 Segment, Geographic and Other Revenue Information HTML 116K
- Footnotes (Detail)
161: R145 Segment, Geographic and Other Revenue Information HTML 68K
- Revenues By Geographic Area (Detail)
162: R146 Segment, Geographic and Other Revenue Information HTML 63K
- Revenues By Geographic Area - Footnotes (Detail)
163: R147 Segment, Geographic and Other Revenue Information HTML 70K
- Long-Lived Assets By Geographic Region (Detail)
164: R148 Segment, Geographic and Other Revenue Information HTML 246K
- Revenues By Products (Detail)
165: R149 Subsequent Event (Details) HTML 81K
167: XML IDEA XML File -- Filing Summary XML 340K
166: EXCEL IDEA Workbook of Financial Reports XLSX 294K
11: EX-101.INS XBRL Instance -- pfe-20161231 XML 13.92M
13: EX-101.CAL XBRL Calculations -- pfe-20161231_cal XML 579K
14: EX-101.DEF XBRL Definitions -- pfe-20161231_def XML 2.77M
15: EX-101.LAB XBRL Labels -- pfe-20161231_lab XML 4.59M
16: EX-101.PRE XBRL Presentations -- pfe-20161231_pre XML 3.38M
12: EX-101.SCH XBRL Schema -- pfe-20161231 XSD 526K
168: ZIP XBRL Zipped Folder -- 0000078003-17-000014-xbrl Zip 972K
 | Download this zipped .zip folder |
| Files: | pfe-20161231.xml pfe-20161231.xsd pfe-20161231_cal.xml pfe-20161231_def.xml pfe-20161231_lab.xml pfe-20161231_pre.xml |